Near-Infrared Fluorescence Imaging of Both Colorectal Cancer and Ureters Using a Low-Dose Integrin Targeted Probe

Annals of Surgical Oncology

Volumn 21, Issue 4, 2014, Pages 528-537

  Verbeek, Floris P R ^a   van der Vorst, Joost R ^a   Tummers, Quirijn R J G ^a   Boonstra, Martin C ^a   de Rooij, Karien E ^a,b   Löwik, Clemens W G M ^a   Valentijn, A Rob P M ^a   van de Velde, Cornelis J H ^a   Choi, Hak Soo ^c   Frangioni, John V ^c   Vahrmeijer, Alexander L ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b PERCUROS B V   (Netherlands)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC ARGININE-GLYCINE-ASPARTIC ACID PEPTIDE; CYCLOPEPTIDE; FLUORESCENT DYE; INTEGRIN; QUATERNARY AMMONIUM DERIVATIVE; SULFONIC ACID DERIVATIVE; ZW800-1 COMPOUND;

ANIMAL; CANCER TRANSPLANTATION; COLORECTAL NEOPLASMS; DIAGNOSTIC USE; FEMALE; FLUORESCENCE IMAGING; HT 29 CELL LINE; HUMAN; INTRAOPERATIVE PERIOD; MOUSE; PROCEDURES; URETER;

ANIMALS; COLORECTAL NEOPLASMS; FEMALE; FLUORESCENT DYES; HT29 CELLS; HUMANS; INTEGRINS; INTRAOPERATIVE PERIOD; MICE; NEOPLASM TRANSPLANTATION; OPTICAL IMAGING; PEPTIDES, CYCLIC; QUATERNARY AMMONIUM COMPOUNDS; SULFONIC ACIDS; URETER;

EID: 84893193841     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-3524-x     Document Type: Article

References (48)

1. Vahrmeijer AL, Frangioni JV. Seeing the invisible during surgery. Br J Surg. 2011;98:749–50.
2. Selzman AA, Spirnak JP. Iatrogenic ureteral injuries: a 20-year experience in treating 165 injuries. J Urol. 1996;155:878–81.
3. Delacroix SE, Jr., Winters JC. Urinary tract injuries: recognition and management. Clin Colon Rectal Surg. 2010;23:221.
4. Preston JM. Iatrogenic ureteric injury: common medicolegal pitfalls. BJU Int. 2000;86:313–7.
5. Frangioni JV. In vivo near-infrared fluorescence imaging. Curr Opin Chem Biol. 2003;7:626–34.
6. Vahrmeijer AL, Hutteman M, van der Vorst JR, van de Velde CJ, Frangioni JV. Image-guided cancer surgery using near-infrared fluorescence. Nat Rev Clin Oncol. 2013;10:507–18.
7. Pleijhuis RG, Graafland M, deVJ, Bart J, deJong JS, vanDam GM. (2009) Obtaining adequate surgical margins in breast-conserving therapy for patients with early-stage breast cancer: current modalities and future directions. Ann Surg Oncol. 16:2717–30.
8. Oliveira S, van Dongen GA, Stigter-van WM, Roovers RC, Stam JC, Mali W, et al. Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody. Mol Imaging. 2012;11:33–46.
9. Themelis G, Harlaar NJ, Kelder W, Bart J, Sarantopoulos A, van Dam GM, et al. Enhancing surgical vision by using real-time imaging of alphavbeta3-integrin targeted near-infrared fluorescent agent. Ann Surg Oncol. 2011;18:3506–13.
10. Heath CH, Deep NL, Sweeny L, Zinn KR, Rosenthal EL. Use of panitumumab-IRDye800 to image microscopic head and neck cancer in an orthotopic surgical model. Ann Surg Oncol. 2012;19:3879–87.
11. Metildi CA, Tang CM, Kaushal S, Leonard SY, Magistri P, Tran Cao HS, et al. (2013) In vivo fluorescence imaging of gastrointestinal stromal tumors using fluorophore-conjugated anti-KIT antibody. Ann Surg Oncol. 20:693–700.
12. van der Vorst JR, Hutteman M, Mieog JS, de Rooij KE, Kaijzel EL, Löwik CW, et al. Near-infrared fluorescence imaging of liver metastases in rats using indocyanine green. J Surg Res. 2011;174:266–71.
13. Keereweer S, Mol IM, Vahrmeijer AL, VanDriel PB, BaatenburgdeJong RJ, Kerrebijn JD, et al. (2012) Dual wavelength tumor targeting for detection of hypopharyngeal cancer using near-infrared optical imaging in an animal model. Int J Cancer. 131:1633–40.
14. Wu Y, Cai W, Chen X. Near-infrared fluorescence imaging of tumor integrin alpha v beta 3 expression with Cy7-labeled RGD multimers. Mol Imaging Biol. 2006;8:226–36.
15. Choi HS, Gibbs SL, Lee JH, Kim SH, Ashitate Y, Liu F, et al. Targeted zwitterionic near-infrared fluorophores for improved optical imaging. Nat Biotechnol. 2013;31:148–53.
16. Metildi CA, Kaushal S, Luiken GA, Talamini MA, Hoffman RM, Bouvet M. (2013) Fluorescently labeled chimeric anti-CEA antibody improves detection and resection of human colon cancer in a patient-derived orthotopic xenograft (PDOX) nude mouse model. J Surg Oncol. doi:10.1002/jso.23507.
17. 3 expression. ChemBioChem. 2012;13:1039–45.
18. Tucker GC. Integrins: molecular targets in cancer therapy. Curr Oncol Rep. 2006;8:96–103.
19. Barczyk M, Carracedo S, Gullberg D. Integrins. Cell Tissue Res. 2010;339:269–80.
20. Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol. 1996;12:697–715.
21. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer. 2002;2:91–100.
22. Vonlaufen A, Wiedle G, Borisch B, Birrer S, Luder P, Imhof BA. Integrin alpha(v)beta(3) expression in colon carcinoma correlates with survival. Mod Pathol. 2001;14:1126–32.
23. Vonlaufen A, Wiedle G, Borisch B, Birrer S, Luder P, Imhof BA. Integrin alpha(v)beta(3) expression in colon carcinoma correlates with survival. Mod Pathol. 2001;14:1126–32.
24. Max R, Gerritsen RR, Nooijen PT, Goodman SL, Sutter A, Keilholz U, et al. Immunohistochemical analysis of integrin alpha vbeta3 expression on tumor-associated vessels of human carcinomas. Int J Cancer. 1997;71:320–4.
25. Axelsson R, Bach-Gansmo T, Castell-Conesa J, McParland BJ. An open-label, multicenter, phase 2a study to assess the feasibility of imaging metastases in late-stage cancer patients with the alpha(v)beta(3)-selective angiogenesis imaging agent (99m)Tc-NC100692. Acta Radiol. 2010;51:40–6.
26. Huang R, Vider J, Kovar JL, Olive DM, Mellinghoff IK, Mayer-Kuckuk P, et al. Integrin αvbeta3-targeted IRDye 800CW near-infrared imaging of glioblastoma. Clin Cancer Res. 2012;18:5731–40.
27. Edwards WB, Akers WJ, Ye Y, Cheney PP, Bloch S, Xu B, et al. Multimodal imaging of integrin receptor-positive tumors by bioluminescence, fluorescence, gamma scintigraphy, and single-photon emission computed tomography using a cyclic RGD peptide labeled with a near-infrared fluorescent dye and a radionuclide. Mol Imaging. 2009;8:101–10.
28. Beer AJ, Kessler H, Wester HJ, Schwaiger M. PET imaging of integrin alphaVbeta3 expression. Theranostics. 2011;1:48–57.
29. Harlaar NJ, Kelder W, Sarantopoulos A, Bart J, Themelis G, van Dam GM, et al. Real-time near infrared fluorescence (NIRF) intra-operative imaging in ovarian cancer using an alpha(v)beta(3-)integrin targeted agent. Gynecol Oncol. 2013;128:590–5.
30. 18F]galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res. 2006;12:3942–9.
31. 18F-galacto-RGD PET. J Nucl Med. 2008;49:255–9.
32. 18F] galacto-RGD positron emission tomography. Neuro Oncol. 2009;11:861–70.
33. Choi HS, Nasr K, Alyabyev S, Feith D, Lee JH, Kim SH, et al. Synthesis and in vivo fate of zwitterionic near-infrared fluorophores. Angew Chem Int Ed Engl. 2011;50:6258–63.
34. 18F)-galacto-RGD and can be produced with high specific activity in a cGMP/GRP compliant automated process. Nucl Med Biol. 2012;39:777–84.
35. Tseng W, Leong X, Engleman E. Orthotopic mouse model of colorectal cancer. J Vis Exp. 2007;(10):484.
36. Troyan SL, Kianzad V, Gibbs-Strauss SL, Gioux S, Matsui A, Oketokoun R, et al. The FLARE intraoperative near-infrared fluorescence imaging system: a first-in-human clinical trial in breast cancer sentinel lymph node mapping. Ann Surg Oncol. 2009;16:2943–52.
37. Intes X, Ripoll J, Chen Y, Nioka S, Yodh AG, Chance B. In vivo continuous-wave optical breast imaging enhanced with indocyanine green. Med Phys. 2003;30:1039–47.
38. Keereweer S, Mol IM, Kerrebijn JD, VanDriel PB, Xie B, BaatenburgdeJong RJ, et al. (2012) Targeting integrins and enhanced permeability and retention (EPR) effect for optical imaging of oral cancer. J Surg Oncol. 105:714–8.
39. Arias JL. Drug targeting strategies in cancer treatment: an overview. Mini Rev Med Chem. 2011;11:1–17.
40. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65:271–84.
41. Fang J, Nakamura H, Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011;63:136–51.
42. Verbeek FP, van der Vorst JR, Schaafsma BE, Swijnenburg RJ, Gaarenstroom KN, Elzevier HW, et al. Intraoperative near infrared fluorescence guided identification of the ureters using low dose methylene blue: a first in human experience. J Urol. 2013;190:574–9.
43. Sherwinter DA. Identification of anomolous biliary anatomy using near-infrared cholangiography. J Gastrointest Surg. 2012;16:1814–5.
44. Verbeek FP, Schaafsma BE, Tummers QR, van der Vorst JR, van der Made WJ, Baeten CI, et al. Optimization of near-infrared fluorescence cholangiography for open and laparoscopic surgery. Surg Endosc. 2013 (in press).
45. 18F-galacto-RGD in cancer patients. J Nucl Med. 2005;46:1333–41.
46. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 2001;61:1781–5.
47. US Department of Health and Human Services, Center for Drug Evaluation and Research. Guidance for industry, investigators, and reviewers exploratory IND studies. Rockville, MD: US Department of Health and Human Services; 2006.
48. Scheuer W, van Dam GM, Dobosz M, Schwaiger M, Ntziachristos V. Drug-based optical agents: infiltrating clinics at lower risk. Sci Transl Med. 2012; 4: 134ps11.